ellagic acid

Small moleculeexperimental

Ellagic acid is a dilactone of hexahydroxydiphenic acid, that found in numerous fruits and vegetables. Ellagic acid was first discovered by chemist Henri Braconnot in 1831. Ellagic acid is found in oaks species like the North American white oak (Quercus alba) and European red oak (Quercus robur). The highest levels of ellagic acid are found in walnuts, pecans, cranberries, raspberries, strawberries, and grapes, as well as distilled beverages. It is also found in peach, and other plant foods. Ellagic acid has antiproliferative and antioxidant properties in a number of in vitro and small-animal models. The antiproliferative properties of ellagic acid may be due to its ability to directly inhibit the DNA binding of certain carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons. As with other polyphenol antioxidants, ellagic acid has a chemoprotective effect in cellular models by reducing oxidative stress. Ellagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement of cardiovascular function in adolescents who are obese (phase 2 trial), and topical treatment of solar lentigines. Ellagic acid has been marketed as a dietary supplement with a range of claimed benefits against cancer, heart disease, and other medical problems. Ellagic acid has been identified by the U.S. Food and Drug Administration as a "fake cancer 'cure' consumers should avoid". — NCATS

Clinical trial activity

6 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2003 (NCT00728299)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetAntioxidant

    antioxidant

Chemistry & pharmacology

Loading structure…

SMILES

OC1=C(O)C2=C3C(=C1)C(=O)OC4=C3C(=CC(O)=C4O)C(=O)O2
Mol. weight
302.1926 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • benzoaric acid
  • benzoaric acid
  • ellagic acid
  • ellagic acid
  • ellagic acid
  • ellagic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07182370N/AJan 15, 2024Government of Spain, Universidad de Murcia
NCT04011618Phase 2Sep 30, 2019Government of Mexico, University of Guadalajara
NCT03713164Phase 1/Phase 2 (Phase 2)Feb 22, 2018University of California, Los Angeles
NCT02263378N/ASep 1, 2014University of Messina
NCT00455416Phase 2Apr 1, 2007Osaka University, University of Oslo
NCT00728299N/ASep 1, 2003POM Wonderful LLC, Radiant Research
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of MexicoGovernment1012019
Government of SpainGovernment1112024
Osaka UniversityAcademic/Hospital1112007
POM Wonderful LLCFor profit1012003
Radiant ResearchAcademic/Hospital1112003
Universidad de MurciaAcademic/Hospital1012024
University of California, Los AngelesAcademic/Hospital1112018
University of GuadalajaraAcademic/Hospital1112019
University of MessinaAcademic/Hospital1112014
University of OsloAcademic/Hospital1012007
10 organizations
Page 1 / 1